Endocrine Abstracts

Since 2007 GLP-1 receptor agonists (GLP-1 analogues or incretins) are used for the treatment of type 2 diabetes mellitus. The mechanism of action includes stimulation of insulin secretion from pancreatic β-cells, inhibition of glucagon secretion from α-cells, induction of important β-cell specific genes (e.g. proinsulin, glucokinase and GLUT-2), reduction of postprandial glucose excursions by inhibition of gastric emptying and lowering of overall energy intake v...